512 related articles for article (PubMed ID: 31778911)
21. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Mesa RA; Verstovsek S; Cervantes F; Barosi G; Reilly JT; Dupriez B; Levine R; Le Bousse-Kerdiles MC; Wadleigh M; Campbell PJ; Silver RT; Vannucchi AM; Deeg HJ; Gisslinger H; Thomas D; Odenike O; Solberg LA; Gotlib J; Hexner E; Nimer SD; Kantarjian H; Orazi A; Vardiman JW; Thiele J; Tefferi A;
Leuk Res; 2007 Jun; 31(6):737-40. PubMed ID: 17210175
[TBL] [Abstract][Full Text] [Related]
22. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
Pardanani A; Tefferi A; Guglielmelli P; Bogani C; Bartalucci N; Rodríguez J; Extremera S; Pérez I; Alfaro V; Vannucchi AM
Blood Cancer J; 2015 Mar; 5(3):e286. PubMed ID: 25768401
[TBL] [Abstract][Full Text] [Related]
25. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Pardanani A; Gotlib JR; Jamieson C; Cortes JE; Talpaz M; Stone RM; Silverman MH; Gilliland DG; Shorr J; Tefferi A
J Clin Oncol; 2011 Mar; 29(7):789-96. PubMed ID: 21220608
[TBL] [Abstract][Full Text] [Related]
27. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
[TBL] [Abstract][Full Text] [Related]
28. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
29. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Verstovsek S; Savona MR; Mesa RA; Dong H; Maltzman JD; Sharma S; Silverman J; Oh ST; Gotlib J
Br J Haematol; 2017 Mar; 176(6):939-949. PubMed ID: 28220932
[TBL] [Abstract][Full Text] [Related]
30. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Bose P; Verstovsek S
J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
[TBL] [Abstract][Full Text] [Related]
31. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
[TBL] [Abstract][Full Text] [Related]
33. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
34. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
Tefferi A; Pardanani A
Mayo Clin Proc; 2011 Dec; 86(12):1188-91. PubMed ID: 22034658
[TBL] [Abstract][Full Text] [Related]
35. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F; Ross DM; Radinoff A; Palandri F; Myasnikov A; Vannucchi AM; Zachee P; Gisslinger H; Komatsu N; Foltz L; Mannelli F; Passamonti F; Gilotti G; Sadek I; Tiwari R; Zor E; Al-Ali HK
Leukemia; 2021 Dec; 35(12):3455-3465. PubMed ID: 34017073
[TBL] [Abstract][Full Text] [Related]
37. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
38. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Ogasawara K; Zhou S; Krishna G; Palmisano M; Li Y
Cancer Chemother Pharmacol; 2019 Oct; 84(4):891-898. PubMed ID: 31444617
[TBL] [Abstract][Full Text] [Related]
40. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
